• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy
【24h】

The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy

机译：曲美他嗪对糖尿病合并特发性扩张性心肌病患者心功能的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: Trimetazidine is an anti-ischemic metabolic agent which improves myocardial glucose utilization. Whether it may improve cardiac function and physical tolerance in diabetic patients with idiopathic dilated cardiomyopathy is still not confirmed. In this study we have investigated the effectiveness of trimetazidine in these patients. Main methods: Volunteers with diabetes and idiopathic dilated cardiomyopathy were recruited for participation in this study. Patients were randomized into two groups. One group received trimetazidine (20 mg, t.i.d.) for 6 months (n = 40), while another group received a placebo during the same period (n = 40). All patients received an echocardiographic examination, 6-minute walk test and an inflammation biochemical analysis (C reactive protein) at baseline and after 6 months of treatment. Key findings: No significant adverse events or changes in clinical or biochemical parameters were detected through the study. After 6 months, TMZ-treated patients had a significant improvement in systolic function as compared with control patients associated with an increased ratio of E/A. C reactive protein concentrations remained stable throughout the study in trimetazidine group at baseline and at the 6 month on follow up. In comparison, it increased significantly in the control group at the 6-month follow up. The NT-pro BNP levels did not change in the control group, whereas they significantly decreased in the trimetazidine group. The physical activity tolerance level improved in the trimetazidine group compared to the control group. Significance: Trimetazidine treatment was associated with a significant improvement of cardiac function and physical tolerance. Results also suggested that the inflammatory response was decreased in trimetazidine group as compared with control patients. ? 2012 Elsevier Inc.
机译：目的：曲美他嗪是一种抗缺血性代谢药物，可提高心肌葡萄糖的利用率。尚不清楚是否可以改善糖尿病合并特发性扩张型心肌病的患者的心功能和身体耐受性。在这项研究中，我们研究了曲美他嗪在这些患者中的有效性。主要方法：招募患有糖尿病和特发性扩张型心肌病的志愿者参加这项研究。将患者随机分为两组。一组接受曲美他嗪（20 mg，t.i.d。）治疗6个月（n = 40），而另一组在同一时期接受安慰剂（n = 40）。所有患者在基线和治疗6个月后均接受了超声心动图检查，6分钟步行测试和炎症生化分析（C反应蛋白）。关键发现：通过研究未发现重大不良事件或临床或生化指标变化。 6个月后，与对照组相比，经TMZ治疗的患者的收缩功能有了显着改善，而E / A比例增加。在整个研究中，曲美他嗪组的C反应蛋白浓度在基线和随访的6个月内保持稳定。相比之下，在随访6个月的对照组中，其显着增加。 NT-pro BNP水平在对照组中没有变化，而在曲美他嗪组中则显着下降。与对照组相比，曲美他嗪组的身体活动耐力水平有所提高。意义：曲美他嗪治疗可显着改善心脏功能和身体耐受性。结果还表明曲美他嗪组的炎症反应与对照组相比有所降低。 ？ 2012爱思唯尔公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号